Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxostephanine is a **naturally occurring aporphine alkaloid** isolated from various plants of the genus **Stephania** (notably Stephania dielsiana and Stephania venosa). It is characterized as an inhibitor of **Aurora kinases** (Aurora A, B, and C), which are crucial enzymes involved in cell division. Oxostephanine works by preventing histone H3 phosphorylation at serine 10, inducing mislocalization of Aurora B, and resulting in aneuploidy. It exhibits selective **cytotoxicity against cancer cells**, including ovarian, breast, hepatocellular, leukemia, and other tumor cell lines, while showing minimal toxicity to normal cells. In addition to its anti-mitotic effects, oxostephanine also **inhibits angiogenesis** by attenuating migration and tube formation of endothelial cells. The molecule has not reached clinical application and remains in preclinical research phases, but it is seen as a lead compound for cancer therapy targeting both Aurora kinases and tumor angiogenesis[1][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxostephanine.